# Jeito Capital

Source: https://onco.cc/companies/jeito-capital/  
OnCo record `jeito-capital` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Jeito Capital is a Paris fund that writes large cheques for European biotech companies so they can take drugs through late-stage trials without selling early. Cancer medicines are a recurring theme.

## Summary

Jeito Capital is a Paris-based growth-stage life-science investor founded in 2018 by Rafaele Tordjman, with a stated focus on patient benefit and on giving European biopharma companies the capital to run pivotal programmes and build commercial capabilities in Europe rather than out-licensing early. It participates in and leads large Series B and C rounds, several of them in oncology; the portfolio links in OnCo are derived from the startup records that name it.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: vc
- HQ: Paris
- Type: investor
- Website: https://www.jeito.life

## Sources

- Official website: https://www.jeito.life

## Connected records

- companies: [Adcendo](https://onco.cc/companies/adcendo/), [Alentis Therapeutics](https://onco.cc/companies/alentis-therapeutics/), [Callio Therapeutics](https://onco.cc/companies/callio-therapeutics/), [Neogene Therapeutics](https://onco.cc/companies/neogene-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/jeito-capital.json